Non-metastatic Castration-resistant Prostate Cancer
Oncology·MeSH: Neoplasm Metastasis
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
1 drug in development·1 company·3 clinical trials
Drug Pipeline by Phase
Phase 4(1)
Frequently asked questions
How many drugs are in development for Non-metastatic Castration-resistant Prostate Cancer?
BioSniper tracks 1 drug in development for Non-metastatic Castration-resistant Prostate Cancer across 1 company.
How many clinical trials target Non-metastatic Castration-resistant Prostate Cancer?
There are 3 clinical trials targeting Non-metastatic Castration-resistant Prostate Cancer tracked by BioSniper.
What is the prevalence of Non-metastatic Castration-resistant Prostate Cancer?
The estimated prevalence of Non-metastatic Castration-resistant Prostate Cancer is approximately 256.0 per 100,000 population.
Deep-dive into Non-metastatic Castration-resistant Prostate Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis